Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer

Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most patients develop disease relapse shortly after definitive treatment. The landmark trials IMpower133 and CASPIAN demonstrated a survival benefit with the addition of immunotherapy to first-line platinum/eto...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlick, Brian, Shields, Misty Dawn, Marin-Acevedo, Julian A., Patel, Ishika, Pellini, Bruna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Lung Cancer (TA Leal and N Sethakorn, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345799/
https://www.ncbi.nlm.nih.gov/pubmed/35716328
http://dx.doi.org/10.1007/s11864-022-00989-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345799/
https://www.ncbi.nlm.nih.gov/pubmed/35716328
http://dx.doi.org/10.1007/s11864-022-00989-7

Ejemplares similares